Because of missing data concerning the response of different intrinsic breast cancer subtypes to adjuvant therapy, polychemotherapy was applied to most affected women with localized breast cancer irrespective of menopausal status, affected lymph nodes, tumor subtype or hormone receptor status [1–3]. The gene discussed is NR4A1; the disease is neoplasm.